Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc., is based in STAMFORD, Conn.
| Revenue (Most Recent Fiscal Year) | $7.14M |
| Net Income (Most Recent Fiscal Year) | $-18.21M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.13 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -145.40% |
| Return on Assets (Trailing 12 Months) | -91.11% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.87 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.87 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.23 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.69 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.26 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 13.34M |
| Free Float | 12.35M |
| Market Capitalization | $13.47M |
| Average Volume (Last 20 Days) | 0.24M |
| Beta (Past 60 Months) | 0.38 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 44.66% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |